DS Healthcare Group Files U.S. Patent on New Compound for Hair Loss
Marks 2nd patent filed in six months as Company builds its intellectual
Pompano Beach, Fla., May 8, 2014 (GLOBE NEWSWIRE) -- DS Healthcare Group, Inc.
(NASDAQ: DSKX), a leading developer of personal care products, today announced
it has filed its second patent with the U.S. Patent and Trademark Office. This
new patent addresses the composition and methods of a new compound described
as a calcium-activated potassium channel opening agent for topical treatment
of hair loss. DS Healthcare hadfiled its first patentin October 2013 for its
prescription hair loss product currently under development.
We believe this newly filed patent-pending molecule offers a more effective
over-the-counter hair loss solution than FDA approved topical minoxidil for
hair regrowth. DS Healthcare's proprietary hair loss formulations are a
tremendous asset and we are building our IP portfolio including patents, as
well as trademarks for our industry-leading brands. While sales of our
over-the-counter products continue to grow driven by strong consumer demand,
in parallel we are developing our first prescription hair loss product,"
stated DS Healthcare President and CEO Daniel Khesin.
About DS Healthcare Group
DS Healthcare Group Inc. leads in the development of biotechnology for topical
therapies. It markets through online and specialty retailers, distributors,
cosmetics wholesalers, and salons. Its research has led to a highly innovative
portfolio of personal care products and additional innovations in
pharmaceutical projects. For more information on DS Health Group's flagship
Except for statements of historical fact, the matters discussed in this press
release are forward-looking and made pursuant to the Safe Harbor provisions of
the Private Securities Litigation Reform Act of 1995. "Forward-looking
statements" describe future expectations, plans, results, or strategies, and
are generally preceded by words such as "future," "plan" or "planned,"
"expects," or "projected." These forward-looking statements reflect numerous
assumptions and involve a variety of risks and uncertainties, many of which
are beyond the company's control that may cause actual results to differ
materially from stated expectations. These risk factors include, among others,
limited operating history, difficulty in developing and marketing products,
intense competition, and additional risks factors as discussed in reports
filed by the company with the Securities and Exchange Commission, which are
CONTACT: Laurel Moody
DS Healthcare Group,Inc.
Press spacebar to pause and continue. Press esc to stop.